Ottawa, Ontario, Canada
June 20, 2022
Cannabis Orchards Inc., a biotechnology company focusing on the research, development and commercialization of minor cannabinoids and innovative industrial hemp varieties, announced it has signed an exclusive partnership agreement with Front Range Biosciences (FRB), an American cannabis and hemp genetics platform company based in Boulder, Colorado that specializes in creating and introducing new innovative products, by combining their own innovative agricultural technologies with their world renowned hemp and cannabis Research & Development program.
Cannabis Orchards Inc. will exclusively distribute feminized hemp seed from select Front Range Biosciences varieties and genetics in Canada, which align with the collective goal of making available hemp varieties rich in minor cannabinoids, upon approval by Health Canada. These varieties include:
- Valerie-16:
- Cannabichromene (CBC) rich strain, 24-28:1 CBD:THC, 13-16% CBD, 3-4% CBC when grown under optimal conditions
- Rich in terpenes Myrcene and Caryophyllene which lend themselves to give this variety its aroma of musk, clove, herbal, citrus, wood, and spice.
- Valerie-29:
- CBD and CBC Dominant Sativa, 26-30:1 CBD:THC, 15-18% CBD, 3-5% CBC when grown under optimal conditions
- Dominantly citrus in aroma. Rich in terpenes Myrcene and Caryophyllene which lend themselves to give this variety its aroma of musk, clove, herbal, citrus, wood, and spice.
Statement from Cannabis Orchards CEO, Dr. Jamie Ghossein
“The partnership agreement with FRB will enable us to scale the production of cannabichromene, making this novel cannabinoid available to cannabis companies and consumers across Canada. More importantly, this will finally allow us to lend this novel cannabinoid for study to researchers and clinicians across Canada, allowing us to develop new therapeutic options for patients and the medicinal market.”
Potential CBC Benefits
CBC has been largely unavailable in the Canadian hemp market up until recently. Even now, CBC is often undetectable and found in trace amounts. Many plants considered to be high in CBC only exhibit a concentration of 0.4-0.8% CBC. By introducing Valerie-16 and Valerie-29 which can yield CBC up to 3-4% availability drastically increases the yield for cannabis extractors. With interest in CBC increasing and more scientific evidence on the benefits of CBC being published now is the perfect time to get into the market with CBC-predominant products.
CBC, like all other minor cannabinoids, comes from the mother of all cannabinoids, Cannabigerol (CBG). However, unlike CBG, which is only expressed in higher concentrations at the reduction of other therapeutic cannabinoids, CBC is able to be expressed in tandem with higher concentrations of therapeutic cannabinoids like CBD. It is hypothesized that there is an entourage effect when CBC is combined with other cannabinoids.
What makes CBC unique is its molecular structure which interacts with the human immune system. CBC is able to interact with transient receptor potential (TRP) cation channels that inhibit endocannabinoid inactivation, and thus stimulate CB2 receptors. CBC does not have any significant activity at CB1 receptors, meaning it is a non-psychotropic cannabinoid, and will not alter perception or behaviour as THC does. CBC indirectly affects the endocannabinoid system as it stimulates the production of endocannabinoids, anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG). The endocannabinoid system and transient receptor potential channel are both involved in inflammation and pain.
The growing body of research into the benefits of CBC shows a variety of therapeutic potentials. In vitro and in vivo studies recently published describe that CBC has anti-cancer activity, pain-relieving properties, anti-inflammatory properties and more. At Cannabis Orchards Inc., we see the value of minor cannabinoids and we hope to make CBC widely available to Canadian consumers, patients and researchers for potential therapeutic applications.
Topics
Species
